Profile of:
Irene Van der Horst -Bruinsma
Irene E. van der Horst-Bruinsma is since December 2021 Head of the Department of Rheumatology and Full Professor at the Radboud University Medical Center in Nijmegen. Her main focus of research is sex and gender aspects in musculoskeletal inflammatory diseases, especially in Spondyloarthitis. Following the completion of her Medical Degree at the University of Leiden in 1987, she was trained in Internal Medicine and Rheumatology at the Leiden University Medical Centre and became a Rheumatologist in 1997. In 1998 she completed her PhD thesis at the Leiden University called “The relationship between HLA Class II polymorphisms and the susceptibility to and progression of rheumatoid arthritis.” From 1998 until 2021 she has been working as a senior staff member at the Rheumatology department of the Amsterdam UMC, location VUmc and as head of the Center of Excellence in Ankylosing Spondylitis. In 2018 she was appointed as Full Professor in Gender aspects of rheumatic diseases at the VU University in Amsterdam. She has supervised over 10 PhD theses and has over 200 peer reviewed publications. Prof Irene van der Horst-Bruinsma was member of the ASAS Executive Committee and is now member of the Advisory Board. She is also member of the EUROSpA steering group, of the IGAS steering committee, Executive Board Dutch Society of Gender and Health (Ned Vereniging voor Gender en Gezondheid, NVG&G).
Full name: Irene Van der Horst -Bruinsma
Current country: Netherlands
Membership level: Full
Type of membership: Advisory Board
Number of publications: 21
Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from the EuroSpA Research Collaboration Network (2023)
https://pubmed.ncbi.nlm.nih.gov/37975166
Eder L, James AJ, van der Horst-Bruinsma I, Coates LC, Goel N. Diversity, Equity, and Inclusion: Sex and Gender and Intersectionality With Race and Ethnicity in Psoriatic Disease (2023)
https://pubmed.ncbi.nlm.hov/37527854
Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target. (2023)
https://pubmed.ncbi.nlm.nih.gov/37021937
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data (2023)
https://pubmed.ncbi.nlm.nih.gov/36810788
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data (2023)
https://pubmed.ncbi.nlm.nih.gov/36810788
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data (2023)
https://pubmed.ncbi.nlm.nih.gov/36810788
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data (2023)
https://pubmed.ncbi.nlm.nih.gov/36810788
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data (2023)
https://pubmed.ncbi.nlm.nih.gov/36810788
van Bentum RE, Verbraak FD, Wolf S, Ongkosuwito J, Boers M, Tan HS, van der Horst-Bruinsma IE. High prevalence of previously undiagnosed axial spondyloarthritis in patients referred with anterior uveitis and chronic back pain – the SpEYE study. (2022)
https://pubmed.ncbi.nlm.nih.gov/33277982/
Is treatment in patients suspected of non-radiographic Axial Spondyloarthritis effective? Six months results of a placebo-controlled trial. (2021)
https://pubmed.ncbi.nlm.nih.gov/33277982/
Christiansen SN, Ørnbjerg LM, Horskjær Rasmussen S, Loft AG, Askling J, Iannone F, Zavada J, Michelsen B, Nissen M, Onen F, Santos MJ, Pombo-Suarez M, Relas H, Macfarlane GJ, Tomsic M, Codreanu C, Gudbjornsson B, Van der Horst-Bruinsma I, Di Giuseppe D, Glintborg B, Gremese E, Pavelka K, Kristianslund EK, Ciurea A, Akkoc N, Barcelos A, Sánchez-Piedra C, Peltomaa R, Jones GT, Rotar Z, Ionescu R, Grondal G, Van de Sande MGH, Laas K, Østergaard M, Hetland ML. European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response. (2021)
https://pubmed.ncbi.nlm.nih.gov/33277982/
Baniaamam M, Heslinga SC, Boekel L, Konings TC, Handoko ML, Kamp O, van Halm VP, van der Horst-Bruinsma IE, Nurmohamed MT. The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patients-The CARDAS Study. J Clin Med. (2021)
https://pubmed.ncbi.nlm.nih.gov/34768587/
Baniaamam M, Heslinga SC, Konings TC, Handoko ML, Kamp O, van Halm VP, van der Horst-Bruinsma IE, Nurmohamed MT. Aortic root diameter is associated with HLA-B27: identifying the patient with ankylosing spondylitis at risk for aortic valve regurgitation. Rheumatol Int. 2021 (2021)
https://pubmed.ncbi.nlm.nih.gov/34729637/
van der Horst-Bruinsma I, Miceli-Richard C, Braun J, Marzo-Ortega H, Pavelka K, Kivitz AJ, Deodhar A, Bao W, Porter B, Pournara E. A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. Rheumatol Ther. 2021 Dec;8(4):1775-1787 (2021)
https://pubmed.ncbi.nlm.nih.gov/34618347/
Rusman T, Nurmohamed MT, Hoekstra S, van Denderen CJ, van Vollenhoven RF, Boers M, Ter Wee MM, van der Horst-Bruinsma IE. Disease activity in women with ankylosing spondylitis remains higher under Tumour Necrosis Factor inhibitor treatment than in men: a five-year observational study. Scand J Rheumatol. 2021 (2021)
https://pubmed.ncbi.nlm.nih.gov/34726125/
de Jong HMY, de Winter JJH, van der Horst-Bruinsma IE, van Schaardenburg DJ, van Gaalen FA, van Tubergen AM, Weel AEAM, Landewé RBM, Baeten DLP, van de Sande MGH. Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort. (2021)
https://pubmed.ncbi.nlm.nih.gov/34219406/
van der Horst-Bruinsma IE, van Bentum RE, Verbraak FD, Deodhar A, Rath T, Hoepken B, Irvin-Sellers O, Thomas K, Bauer L, Rudwaleit M. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. (2021)
https://pubmed.ncbi.nlm.nih.gov/33854572/
Konsta M, Sakellariou GT, Rusman T, Sfikakis PP, Iliopoulos A, van der Horst-Bruinsma IE. Long-term effect of TNF inhibitors on radiographic progression in ankylosing spondylitis is associated with time-averaged CRP levels. (2021)
https://pubmed.ncbi.nlm.nih.gov/33278588/
Visman I, Heslinga M, van Denderen C, van der Horst-Bruinsma I, Miltenburg A, Meijers J, Nurmohamed M. Favorable effects on the hemostatic system in ankylosing spondylitis patients treated with golimumab. (2021)
https://pubmed.ncbi.nlm.nih.gov/33166729/
Rusman T, van Bentum RE, van der Horst-Bruinsma IE. Sex and gender differences in axial spondyloarthritis: myths and truths. (2020)
https://pubmed.ncbi.nlm.nih.gov/33053194/
van Bentum RE, Baniaamam M, Kinaci-Tas B, van de Kreeke JA, Kocyigit M, Tomassen J, den Braber A, Visser PJ, Ter Wee MM, Serné EH, Verbraak FD, Nurmohamed MT, van der Horst-Bruinsma IE. Microvascular changes of the retina in ankylosing spondylitis, and the association with cardiovascular disease – the eye for a heart study. (2020)
https://pubmed.ncbi.nlm.nih.gov/32967777/